Evidence map›Paper›PMID 34689723›Full record

ArticleTissue barriers2022

Urinary IgG, serum CX3CL1 and miRNA-152-3p: as predictors of nephropathy in Egyptian type 2 diabetic patients.

Aml E Abdou, Haneya A A Anani, Hanan F Ibrahim, Eman Elshohat Ebrahem, Nora Seliem, Eman M I Youssef, Niveen M Ghoraba, Asmaa S Hassan, Marwa A A Ramadan, Eman Mahmoud and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue barriers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Aml E AbdouMicrobiology and Immunology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Haneya A A AnaniMicrobiology and Immunology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Hanan F IbrahimMicrobiology and Immunology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Eman Elshohat EbrahemBiochemistry Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Nora SeliemBiochemistry Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Eman M I YoussefBiochemistry Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Niveen M GhorabaClinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Asmaa S HassanClinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Marwa A A RamadanClinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Eman MahmoudDepartment of Endocrinology and Metabolism, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Shorouk IssaDepartment of Endocrinology and Metabolism, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Hend M MaghrabyInternal Medicine Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Eman K AbdelrahmanInternal Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt.
Hala Ali Mohammed HassanInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Al-Azhar University · EGCairo University · EGPort Said University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to assess the role of urinary IgG, serum CX3CL1 and miRNA 152-3p levels as predictors of nephropathy in type 2 Egyptian diabetic patients. Sixty type 2 diabetic patients and twenty healthy controls were enrolled in a cross-sectional study. Then they were grouped into: three groups based upon urine albumin excretion (UAE). The expression of miRNA 152-3p in serum was measured using quantitative polymerase chain reaction (RTq-PCR). Serum CX3CL1 and urinary IgG concentrations were measured by ELISA. RTq-PCR revealed that serum miRNA-152-3p levels in patients were significantly higher than in controls. There was significant differences between group with normoalbuminuria and groups with diabetic nephropathy DN as regard to age, duration of nephropathy, Albumin/Creatinine ratio (A/C ratio), creatinine, urine IgG, CX3CL1 and HbA1c. In diabetic patients, there was a significant positive correlation between miRNA-152-3p levels and disease duration only as well as significant positive correlations between urinary IgG levels and age, disease duration, serum creatinine, A/C ratio, and urea. Positive correlation between serum fractalkine CX3CL1 level and age, duration of disease, urea, creatinine, A/C ratio, HbA1C and IgG in patient with DN. Serum CX3CL1 level, urinary IgG were significantly increased with the progress of nephropathy so these integrated biomarkers could be used as good predictors for early identification of nephropathy. But miRNA- 152-3p has inadequate prognostic indicator for ESRD progression.

Indexed as

Chemokine CX3CL1Diabetes Mellitus, Type 2Diabetic NephropathiesMicroRNAsAlbuminsCreatinineCross-Sectional StudiesEgyptGlycated HemoglobinHumansImmunoglobulin GUreaAlbuminsChemokine CX3CL1CreatinineCX3CL1 protein, humanGlycated HemoglobinImmunoglobulin GMicroRNAsMIRN152 microRNA, humanUreaAlbuminuriaCX3CL1Diabetic nephropathyFractalkinemiRNA 152-3pUrinary IgG

Identifiers

PMID34689723
PMCPMC9359404
OpenAlexW3208483687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.